Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/7877
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorPoolsup, Nalinee-
dc.contributor.authorPo, A. Li Wan-
dc.contributor.authorOliveira, I. R. de-
dc.creatorPoolsup, Nalinee-
dc.creatorPo, A. Li Wan-
dc.creatorOliveira, I. R. de-
dc.date.accessioned2013-01-16T11:51:04Z-
dc.date.issued2000-
dc.identifier.issn0269-4727-
dc.identifier.urihttp://www.repositorio.ufba.br/ri/handle/ri/7877-
dc.descriptionTexto completo: acesso restrito. p.139–156pt_BR
dc.description.abstractObjective: To evaluate the efficacy of lithium in the treatment of acute mania. Method: Systematic overview of the literature and meta-analysis of randomised controlled trials. Estimation of (i) the differences in the reduction in mania severity scores, and (ii) the ratio and difference in improvement response rates. Results: A total of 658 patients from 12 trials were included. Treatment periods ranged from 3 to 4 weeks. The response rate ratio for lithium against placebo was 1·95 (95%CI 1·17–3·23). The mean number needed to treat was five (95%CI 3–20). Patients were twice as likely to obtain remission with lithium than with chlorpromazine (rate ratio = 1·96, 95%CI 1·02–3·77). The mean number needed to treat was four (95%CI 3–9). Neither carbamazepine nor valproate was more effective than lithium. The response rate ratios were 1·01 (95%CI 0·54–1·88) for lithium compared to carbamazepine and 1·22 (95%CI 0·91–1·64) for lithium against valproate. Haloperidol was no better than lithium on the basis of improvement based on assessment of global severity. The differences in effects between lithium and risperidone were –2·79 (95%CI –4·22 to –1·36) in favour of risperidone with respect to symptom severity improvement and –0·76 (95%CI –1·11 to –0·41) on the basis of reduction in global severity of disease. Symptom and global severity was as well controlled with lithium as with verapamil. Lithium caused more side-effects than placebo and verapamil, but no more than carbamazepine or valproate. Conclusion: The clinical trial evidence suggests that lithium should remain the first line treatment for acute mania.pt_BR
dc.language.isoenpt_BR
dc.sourcehttp://dx.doi.org/10.1046/j.1365-2710.2000.00278.xpt_BR
dc.titleSystematic overview of lithium treatment in acute maniapt_BR
dc.title.alternativeJournal of Clinical Pharmacy and Therapeuticspt_BR
dc.typeArtigo de Periódicopt_BR
dc.identifier.numberv. 25, n. 2pt_BR
dc.embargo.liftdate10000-01-01-
Aparece nas coleções:Artigo Publicado em Periódico (Faculdade de Medicina)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Oliveira.pdf
  Restricted Access
457,16 kBAdobe PDFVisualizar/Abrir Solicitar uma cópia


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.